Theravance Biopharma (TBPH) Non Operating Income (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Non Operating Income data on file, last reported at $3.0 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $3.0 million, up 220.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.2 million (up 179.25% YoY), and the FY2025 annual result was $10.2 million, up 108.42% from the prior year.
• Non Operating Income declined to $3.0 million in Q1 2026 per TBPH's latest filing, from $3.6 million in the prior quarter.
• Over five years, Non Operating Income peaked at $4.1 million in Q3 2025 and troughed at -$375000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $1.8 million in 2023 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 1761.45% in 2022 and fell as far as 60.26% in 2022.
• A 5-year view of Non Operating Income shows it stood at $3.7 million in 2022, then slumped by 50.38% to $1.8 million in 2023, then plunged by 51.06% to $904000.0 in 2024, then jumped by 302.54% to $3.6 million in 2025, then decreased by 17.2% to $3.0 million in 2026.
• Business Quant data shows TBPH's Non Operating Income at $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $4.1 million in Q3 2025.